Use of early chemotherapy for hormone-sensitive prostate cancer: Time for CHAARTED / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
;
(6): 444-445, 2016.
Artículo
en Chino
| WPRIM
| ID: wpr-842874
ABSTRACT
CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer. In addition to overall survival, secondary endpoints such as time to castration resistance, PSA response were also significant for the patients who received early chemotherapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio diagnóstico
Idioma:
Chino
Revista:
Asian Journal of Andrology
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS